Clearside Biomedical gets $20M for drug-device combo for blindness disorders
Clearside Biomedical will use the Series C round to further clinical trials for its drug-device combination for diseases of the eye that cause blindness.
Clearside Biomedical will use the Series C round to further clinical trials for its drug-device combination for diseases of the eye that cause blindness.
A one-year-old company using drug delivery to improve ophthalmic drugs is raising fresh capital to support trials of its microinjection platform. Clearside Biomedical has raised $7.9 million and could continue raising up to $8.5 million, according to a U.S. Securities and Exchange Commission filing made last week. The company is hoping to stave off retinal […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Ophthalmic startup Clearside Biomedical has launched with a $4 million initial round of investment for the company to continue R&D on its lead drug candidate and a novel drug delivery system that could administer that drug in hard to access regions of the eye. Clearside is headquartered in Atlanta but will maintain research operations in […]